Tedalinab

• Description :

  Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1].

• Product Name Alternative :

  GRC-10693

• UNSPSC :

  12352005

• Target :

  Cannabinoid Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/tedalinab.html

• Purity :

  99.94

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=NN(C2=CC=C(F)C=C2F)C3=C1[C@@]4([H])CC[C@]3([H])C4)NC(C)(C)C

• Molecular Formula :

  C19H21F2N3O

• Molecular Weight :

  345.39

• References & Citations :

  [1]Glenmark’s molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  CB2

• CAS Number :

  [916591-01-0]